Cardlytics' (CDLX) Hold Rating Reaffirmed at Needham & Company LLC

Cardlytics (NASDAQ:CDLX - Get Free Report)'s stock had its "hold" rating restated by Needham & Company LLC in a research report issued to clients and investors on Thursday,Benzinga reports.

Cardlytics Stock Down 2.0 %

Shares of CDLX opened at $1.98 on Thursday. The firm has a market cap of $100.63 million, a PE ratio of -0.32 and a beta of 1.62. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 2.40. The company's fifty day moving average is $3.09 and its two-hundred day moving average is $3.52. Cardlytics has a fifty-two week low of $1.77 and a fifty-two week high of $20.52.

Insiders Place Their Bets

In related news, CFO Alexis Desieno sold 8,854 shares of the stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $3.67, for a total transaction of $32,494.18. Following the completion of the sale, the chief financial officer now owns 121,976 shares of the company's stock, valued at approximately $447,651.92. This represents a 6.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Amit Gupta sold 46,857 shares of Cardlytics stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $3.40, for a total transaction of $159,313.80. Following the transaction, the chief executive officer now directly owns 418,637 shares in the company, valued at approximately $1,423,365.80. This trade represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 111,454 shares of company stock worth $391,864 over the last three months. 4.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Cardlytics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GSA Capital Partners LLP lifted its stake in shares of Cardlytics by 1,273.2% in the third quarter. GSA Capital Partners LLP now owns 382,315 shares of the company's stock worth $1,223,000 after acquiring an additional 354,474 shares in the last quarter. Brooktree Capital Management raised its holdings in shares of Cardlytics by 24.7% during the third quarter. Brooktree Capital Management now owns 167,642 shares of the company's stock worth $536,000 after purchasing an additional 33,169 shares during the period. Check Capital Management Inc. CA lifted its holdings in Cardlytics by 10.4% in the third quarter. Check Capital Management Inc. CA now owns 50,650 shares of the company's stock worth $162,000 after acquiring an additional 4,775 shares during the last quarter. Intech Investment Management LLC acquired a new position in Cardlytics during the 3rd quarter valued at approximately $47,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Cardlytics by 3.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 390,343 shares of the company's stock valued at $1,249,000 after acquiring an additional 11,388 shares during the period. 68.10% of the stock is owned by institutional investors and hedge funds.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

Remove Ads

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.